Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retatrutide hits 28% weight loss in Phase 3 A summary of the interesting content that I consumed this past week What I Read This Week: a summary of the content that I consumed this past week Caught My Eye 1) Retatrutide hits 28% weight loss in Phase 3 On May 21, Eli Lilly released Phase 3 results for retatrutide from the 2,339-patient TRIUMPH-1 obesity trial
For research protocols, it requires reconstitution with Bacteriostatic Water
That said, many people respond incredibly well to conservative rehab, even without surgery
T.KnaffD
And the appetite-reducing effects have been tied to slowing sales for brands that sell products such as snacks and ice cream
Novo Nordisk (Present Leader - Semaglutide Portfolio) CagriSema Mechanism: GLP-1 + Amylin agonist Stage: Phase 3 Expected filing: 2026 Weight loss: ~22-23% in trials Amycretin Mechanism: GLP-1 + Amylin Route: injectable + oral research Stage: Phase 2 Next-gen Oral GLP-1 programs Partnership with biotech firms to develop new oral obesity drugs 2
US$ 25.19
US$ 27.53
US$ 27.01
US$ 25.46
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
US$ 27.68
